LY2875358 + Erlotinib + Gefitinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumors
Conditions
Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung
Trial Timeline
Jun 1, 2012 → Aug 1, 2014
NCT ID
NCT01602289About LY2875358 + Erlotinib + Gefitinib
LY2875358 + Erlotinib + Gefitinib is a phase 1 stage product being developed by Eli Lilly for Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT01602289. Target conditions include Solid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01602289 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumors